Moderna announced successful results from a global late-stage trial of its personalized mRNA melanoma vaccine tested with Merck’s Keytruda in more than 1,100 patients with surgically removed advanced or high-risk melanoma. The announcement prompted stock gains for both companies, though the precise size of Moderna’s increase remains disputed between sources. Moderna CEO Stephane Bancel described the outcome as demonstrating clinical benefit for individualized cancer treatment.